ClinicalTrials.gg
CompletedNCT02956044Updated Jul 22, 2021Results posted

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

A Phase 1 interventional study of Bexagliflozin and Metformin in Type2 Diabetes Mellitus, sponsored by Theracos. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-22.

Sponsored by Theracos · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Bexagliflozin · Diabetes Mellitus, Type 2.

Enrollment
9th of 15
54 · median 64
Started
2016
with 4 others
Phase 1
7 of 15
none open now
Registered
8th of 15
by date
Lead sponsor
13 of 15
Theracos

Among the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 5 that started in 2016, is one of 7 in phase 1, and was the 8th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About bexagliflozin

Bexagliflozin: first FDA approval 2023 (BRENZAVVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to examine the drug-drug interaction in your body when given the study drug, bexagliflozin, with three commonly used ant-diabetic medications, metformin, glimepiride or sitagliptin. The study will also evaluate how safe the study drug is and how well the study drug is tolerated when taken with metformin, glimepiride or sitagliptin.

Read the detailed description

A total of 54 healthy subjects were enrolled and assigned to one of three groups of eighteen. Each group participated in one of three open-label, randomized, three treatment period, crossover studies:

  • Group 1: Bexagliflozin/metformin drug-drug interaction (DDI)
  • Group 2: Bexagliflozin/glimepiride DDI
  • Group 3: Bexagliflozin/sitagliptin DDI For each Group, every subject received a single dose of bexagliflozin tablet, 20 mg, alone, a single dose of an oral hypoglycemic agent (OHA) (1000 mg metformin, 2 mg glimepiride, or 100 mg sitagliptin) alone, and the combination of both (bexagliflozin tablet and OHA) alternately in a crossover fashion, with three treatment periods separated by a washout period of at least 7 days. Within each Group, subjects were randomized to one of six treatment sequences in an equal ratio.

To prevent hypoglycemia, subjects assigned to Group 2 (bexagliflozin/glimepiride DDI) received approximately 300 mL of a solution containing 50 g of glucose with study medication at the time of dosing, as well as approximately 75 mL of a solution containing 12.5 g of glucose every 15 minutes for 4 hours post-dose.

For each treatment period in Group 1 (bexagliflozin/metformin DDI) and Group 2 (bexagliflozin/glimepiride DDI), subjects were admitted to the clinic on the day before dosing and stayed in the clinic until 48 h post-dose. For Group 3 (bexagliflozin/sitagliptin DDI), subjects stayed in the clinic until 72 h post-dose.

For all Groups, blood samples for PK analysis were collected in each period prior to dosing (pre-dose) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose. For Group 3, PK blood samples were also collected at 60 and 72 h post-dose. Plasma concentrations of bexagliflozin and OHAs were determined by validated liquid chromatography tandem mass spectrometry (LC MS/MS) assays.

Urine samples for PD analysis were collected in 12 h intervals. For all Groups, urine samples were collected pre-dose (-12 to 0 h) and post-dose at 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h. For Group 3, additional samples at 48 to 60 h and 60 to 72 h post-dose were collected.

03

Conditions studied

  • Type2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with body-mass index () between 18.0 kg/m2 and 32.0 kg/m2
  2. Subjects who are non-smokers for at least 3 months prior to screening
  3. Subjects who are willing and able to be confined to the clinical research facility as required by the protocol

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of allergy to drugs or latex.
  2. Subjects with a history of alcohol or drug dependence in the past 12 months.
  3. Subjects who have donated a significant amount of blood in the past 2 months
  4. Female subjects who are pregnant or breastfeeding
  5. Subjects who are not willing to use an adequate form of during the study and for 30 days after discharge from clinic
  6. Subjects who have taken an drug in the past 30 days or 7 half-lives of the investigational drug, whichever is longer
  7. Subjects who had previously received anti-diabetic medication, including metformin, sitagliptin, glimepiride or drugs of the same class (i.e. biguanides, DPP-4 inhibitors or sulfonylureas), or SGLT2 inhibitors, in the past 3 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Active comparator
    Group 1: Bexagliflozin alone

    Drug: Bexagliflozin

  • Active comparator
    Group 1: Metformin alone

    Drug: Metformin

  • Active comparator
    Group 1: Bexagliflozin + Metformin

    Drug: Bexagliflozin · Drug: Metformin

  • Active comparator
    Group 2: Bexagliflozin alone

    Drug: Bexagliflozin

  • Active comparator
    Group 2: Glimepiride alone

    Drug: Glimepiride

  • Active comparator
    Group 2: Bexagliflozin + Glimepiride

    Drug: Bexagliflozin · Drug: Glimepiride

  • Active comparator
    Group 3: Bexagliflozin alone

    Drug: Bexagliflozin

  • Active comparator
    Group 3: Sitagliptin alone

    Drug: Sitagliptin

  • Active comparator
    Group 3: Bexagliflozin + Sitagliptin

    Drug: Bexagliflozin · Drug: Sitagliptin

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum Observed Plasma Concentration)

    Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations.

    Time frame: Up to 72 hours

  2. Tmax (Time of Maximum Observed Plasma Concentration)

    Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations.

    Time frame: Up to 72 hours

  3. T1/2 (Apparent Terminal Elimination Half-life)

    Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations.

    Time frame: Up to 72 hours

  4. AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)

    Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject.

    Time frame: Up to 72 hours

Secondary outcomes

  1. Urinary Glucose Excretion up to 0-72 hr

    Pre-dose urine samples were collected from -12 to 0 h for baseline measurement. Subjects was instructed to empty their bladder prior to dosing. Post-dose urine was collected in 4 batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 o 36 h, and 36 to 48 h collections. Post-dose urine was collected in batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, 36 to 48 h, 48 to 60 h and 60 to 72 h.

    Time frame: up to 0-72 hr

07

Results

Posted Jul 22, 2021

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin + Sitagliptin
Started181818
Completed181818
Not completed000

Outcome measures

PrimaryCmax (Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations.

Time frame:
Up to 72 hours
Reported as:
Geometric mean · ng/mL
Cmax (Maximum Observed Plasma Concentration)
ng/mLGroup 1: Bexagliflozin AloneGroup 1: Metformin AloneGroup 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin AloneGroup 2: Glimepiride AloneGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin AloneGroup 3: Sitagliptin AloneGroup 3: Bexagliflozin + Sitagliptin
Bexagliflozin PK parameters124.6 ± 43.7—135.5 ± 40.0158.6 ± 53.9—143.7 ± 37.9117.1 ± 34.6—148.3 ± 22.1
Metformin PK parameters—2067.6 ± 27.21965.2 ± 33.6——————
Glimepiride PK parameters————59.9 ± 32.267.1 ± 29.5———
Sitagliptin PK parameters———————356.6 ± 22.3351.2 ± 32.9
Statistical analysis
  • Group 1: Bexagliflozin Alone vs Group 1: Bexagliflozin + Metformin · Ratio of geometric lsm: 108.73 · 95% CI 94.35 to 125.30Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect
  • Group 1: Metformin Alone vs Group 1: Bexagliflozin + Metformin · Ratio of geometric lsm: 95.05 · 90% CI 84.73 to 106.63Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect
  • Group 2: Bexagliflozin Alone vs Group 2: Bexagliflozin + Glimepiride · Ratio of geometric lsm: 89.44 · 90% CI 70.39 to 113.65Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect
  • Group 2: Glimepiride Alone vs Group 2: Bexagliflozin + Glimepiride · Ratio of geometric lsm: 111.95 · 90% CI 97.02 to 129.19Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect
  • Group 3: Bexagliflozin Alone vs Group 3: Bexagliflozin + Sitagliptin · Ratio of geometric lsm: 126.68 · 90% CI 112.08 to 143.17Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect
  • Group 3: Sitagliptin Alone vs Group 3: Bexagliflozin + Sitagliptin · Ratio of geometric lsm: 98.48 · 90% CI 84.90 to 114.23Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect
PrimaryTmax (Time of Maximum Observed Plasma Concentration)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations.

Time frame:
Up to 72 hours
Reported as:
Median · hours
Tmax (Time of Maximum Observed Plasma Concentration)
hoursGroup 1: Bexagliflozin AloneGroup 1: Metformin AloneGroup 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin AloneGroup 2: Glimepiride AloneGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin AloneGroup 3: Sitagliptin AloneGroup 3: Bexagliflozin + Sitagliptin
Bexagliflozin PK parameters4.0 (1 to 5)—3.0 (1 to 5)8.0 (5 to 10)—6.0 (5 to 10)3.0 (2 to 5)—4.0 (2 to 5)
Metformin PK parameters—2.5 (1 to 3)2.0 (1 to 5)—0 (0 to 0)————
Glimepiride PK parameters————5.5 (1 to 10)7.0 (1 to 10)———
Sitagliptin PK parameters———————2.5 (1 to 5)2.5 (1 to 6)
PrimaryT1/2 (Apparent Terminal Elimination Half-life)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations.

Time frame:
Up to 72 hours
Reported as:
Geometric mean · hours
T1/2 (Apparent Terminal Elimination Half-life)
hoursGroup 1: Bexagliflozin AloneGroup 1: Metformin AloneGroup 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin AloneGroup 2: Glimepiride AloneGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin AloneGroup 3: Sitagliptin AloneGroup 3: Bexagliflozin + Sitagliptin
Bexagliflozin PK parameters10.3 ± 30.4—7.8 ± 48.68.0 ± 33.3—7.8 ± 34.412.6 ± 48—13.3 ± 38.2
Metformin PK parameters—9.0 ± 31.810.2 ± 32.5——————
Glimepiride PK parameters————7.8 ± 46.86.6 ± 57.8———
Sitagliptin PK parameters———————14.3 ± 22.314.8 ± 24.5
PrimaryAUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)

Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject.

Time frame:
Up to 72 hours
Reported as:
Geometric mean · h*ng/mL
AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
h*ng/mLGroup 1: Bexagliflozin AloneGroup 1: Metformin AloneGroup 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin AloneGroup 2: Glimepiride AloneGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin AloneGroup 3: Sitagliptin AloneGroup 3: Bexagliflozin + Sitagliptin
Bexagliflozin PK parameters1154.4 ± 35.1—1008.6 ± 40.21204.9 ± 48.6—1162.2 ± 47.81011.8 ± 21.5—1158.1 ± 21.9
Metformin PK parameters—13351.9 ± 22.513784.6 ± 26.0——————
Glimepiride PK parameters————496.1 ± 53.3633.0 ± 38.5———
Sitagliptin PK parameters———————3579.6 ± 14.73692.8 ± 16.9
Statistical analysis
  • Group 1: Bexagliflozin Alone vs Group 1: Bexagliflozin + Metformin · Ratio of geometric lsm: 87.36 · 90% CI 80.02 to 95.38Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect
  • Group 1: Metformin Alone vs Group 1: Bexagliflozin + Metformin · Ratio of geometric lsm: 103.24 · 90% CI 94.59 to 112.68Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect
  • Group 2: Bexagliflozin Alone vs Group 2: Bexagliflozin + Glimepiride · Ratio of geometric lsm: 94.46 · 90% CI 80.34 to 111.06Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect
  • Group 2: Glimepiride Alone vs Group 2: Bexagliflozin + Glimepiride · [ratio of geometric lsm]: 127.19 · 90% CI 110.33 to 146.62Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect
  • Group 3: Bexagliflozin Alone vs Group 3: Bexagliflozin + Sitagliptin · [ratio of geometric lsm]: 113.09 · 90% CI 107.61 to 118.86Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect
  • Group 3: Sitagliptin Alone vs Group 3: Bexagliflozin + Sitagliptin · [ratio of geometric lsm]: 103.16 · 90% CI 99.30 to 107.17
SecondaryUrinary Glucose Excretion up to 0-72 hr

Pre-dose urine samples were collected from -12 to 0 h for baseline measurement. Subjects was instructed to empty their bladder prior to dosing. Post-dose urine was collected in 4 batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 o 36 h, and 36 to 48 h collections. Post-dose urine was collected in batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, 36 to 48 h, 48 to 60 h and 60 to 72 h.

Time frame:
up to 0-72 hr
Reported as:
Mean · g
Urinary Glucose Excretion up to 0-72 hr
gGroup 1: Bexagliflozin AloneGroup 1: Metformin AloneGroup 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin AloneGroup 2: Glimepiride AloneGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin AloneGroup 3: Sitagliptin AloneGroup 3: Bexagliflozin + Sitagliptin
0 - 12 hours31.57 ± 8.060.02 ± 0.0126.26 ± 8.8636.99 ± 14.241.26 ± 4.3731.02 ± 11.1929.01 ± 6.840.03 ± 0.0123.94 ± 7.17
12 - 24 hours17.32 ± 11.810.04 ± 0.0322.57 ± 8.2926.85 ± 9.510.04 ± 0.0522.59 ± 11.1524.38 ± 7.920.04 ± 0.0522.85 ± 9.59
24 - 36 hours23.94 ± 9.160.04 ± 0.0419.50 ± 8.9429.79 ± 10.240.20 ± 0.4228.46 ± 11.3722.31 ± 8.970.17 ± 0.5624.15 ± 9.27
36 - 48 hours8.91 ± 4.970.02 ± 0.015.53 ± 4.1711.03 ± 7.840.03 ± 0.019.34 ± 7.559.83 ± 6.670.03 ± 0.0110.17 ± 5.23
48 - 60 hours——————11.32 ± 8.090.05 ± 0.0711.50 ± 7.52
60 - 72 hours——————2.67 ± 3.550.02 ± 0.012.70 ± 2.91

Adverse events

Collected over Adverse event collection began on the first clinical admission day (Day 0) and continued through D17. The subjects were actively monitored for serious adverse events for at least 14 days after discharge from the study.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Bexagliflozin Alone0/18 (0%)0/18 (0%)3/18 (16.7%)
Group 1: Metformin Alone0/18 (0%)0/18 (0%)11/18 (61.1%)
Group 1: Bexagliflozin + Metformin0/18 (0%)0/18 (0%)13/18 (72.2%)
Group 2: Bexagliflozin Alone0/18 (0%)0/18 (0%)6/18 (33.3%)
Group 2: Glimepiride Alone0/18 (0%)0/18 (0%)2/18 (11.1%)
Group 2: Bexagliflozin + Glimepiride0/18 (0%)0/18 (0%)4/18 (22.2%)
Group 3: Bexagliflozin Alone0/18 (0%)0/18 (0%)3/18 (16.7%)
Group 3: Sitagliptin Alone0/18 (0%)0/18 (0%)1/18 (5.6%)
Group 3: Bexagliflozin + Sitagliptin0/18 (0%)0/18 (0%)2/18 (11.1%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventGroup 1: Bexagliflozin AloneGroup 1: Metformin AloneGroup 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin AloneGroup 2: Glimepiride AloneGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin AloneGroup 3: Sitagliptin AloneGroup 3: Bexagliflozin + Sitagliptin
DiarrheaGastrointestinal disorders0/189/187/180/180/180/180/180/180/18
HeadacheNervous system disorders1/180/184/184/181/181/180/180/180/18
NauseaGastrointestinal disorders0/183/182/182/181/183/180/180/180/18
HypoglycemiaMetabolism and nutrition disorders2/180/180/181/181/180/183/180/180/18
DyspepsiaGastrointestinal disorders0/181/182/180/181/180/180/180/180/18
VomitingGastrointestinal disorders0/180/180/182/181/181/180/180/180/18
Abdominal painGastrointestinal disorders0/180/181/180/180/181/180/180/180/18
Abdominal pain upperGastrointestinal disorders0/181/180/180/180/180/180/180/180/18
FlatulenceGastrointestinal disorders0/180/180/180/180/181/180/180/180/18
TendernessGeneral disorders0/180/181/180/180/180/180/180/180/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin + SitagliptinTotal
Mean42.2 ± 15.6937.6 ± 8.2543.6 ± 14.5241.1 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin + SitagliptinTotal
Female65920
Male1213934
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin + SitagliptinTotal
Hispanic or Latino0011
Not Hispanic or Latino18181753
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin + SitagliptinTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American551020
White1312833
More than one race0000
Unknown or Not Reported0101
Weight
Weight(kg)Group 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin + SitagliptinTotal
Mean79.0 ± 11.7577.9 ± 12.3779.0 ± 13.2178.6 ± 12.23
Height
Height(cm)Group 1: Bexagliflozin + MetforminGroup 2: Bexagliflozin + GlimepirideGroup 3: Bexagliflozin + SitagliptinTotal
Mean173.3 ± 9.16172.3 ± 6.45170.5 ± 8.37172.0 ± 8.01
08

Study locations

1 site
  • Clinical Research Site
    Evansville, Indiana 47710, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2021, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2016
First posted
Nov 4, 2016
Start
Nov 2016
Primary completionActual
Mar 2017
CompletionActual
Mar 2017
Results first posted
Jul 22, 2021
Last update
Jul 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02956044
Lead sponsor
Theracos
Responsible party
Sponsor
First posted
Nov 4, 2016
Start date
Nov 2016
Primary completion
Mar 2017
Completion
Mar 2017
Results posted
Jul 22, 2021
Last update
Jul 22, 2021

Study contacts

Mason Freeman, M.D.
study chair · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bexagliflozin · Metformin · Glimepiride · Sitagliptin

Start the discussion